A Benefit-Risk Assessment of Class III Antiarrhythmic Agents
暂无分享,去创建一个
Bente Brendorp | B. Brendorp | L. Køber | Naji Sahebzadah | C. Torp-Pedersen | Christian Torp-Pedersen | Lars Køber | Ole Dyg Pedersen | Naji Sahebzadah | O. Pedersen
[1] Michael R. Rosen,et al. The 'Sicilian Gambit' - A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms , 1991 .
[2] J. Tsikouris,et al. A Review of Class III Antiarrhythmic Agents for Atrial Fibrillation: Maintenance of Normal Sinus Rhythm , 2001, Pharmacotherapy.
[3] J. Arrowsmith,et al. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. , 1991, The Journal of pharmacology and experimental therapeutics.
[4] C Antzelevitch,et al. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. , 1998, Circulation.
[5] C Antzelevitch,et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.
[6] P. Sager. New advances in class III antiarrhythmic drug therapy , 2000, Current opinion in cardiology.
[7] F. Morady,et al. Immediate reproducibility of clinical and nonclinical forms of induced ventricular tachycardia. , 1986, The American journal of cardiology.
[8] M. Radford,et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. , 1996, Circulation.
[9] S. Yabek,et al. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. , 1986, Journal of the American College of Cardiology.
[10] C Antzelevitch,et al. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. , 1994, Journal of the American College of Cardiology.
[11] J F Leclercq,et al. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. , 1989, American heart journal.
[12] Bertram Pitt,et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.
[13] Y Rudy,et al. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study. , 1999, Cardiovascular research.
[14] M. Keller,et al. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.
[15] M. Brodsky,et al. Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study , 2000, Circulation.
[16] J. Lynch,et al. Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499. , 1994, Journal of cardiovascular pharmacology.
[17] H. Elming,et al. Survival after withdrawal of dofetilide in patients with congestive heart failure and a short baseline QTc interval; a follow-up on the Diamond-CHF QT substudy. , 2003, European heart journal.
[18] B. Lucchesi,et al. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. , 1985, American heart journal.
[19] D. Roden,et al. Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. , 2001, Journal of the American College of Cardiology.
[20] K. Nademanee,et al. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. , 1982, American heart journal.
[21] Thomas L. Lenz,et al. Dofetilide, a New Class III Antiarrhythmic Agent , 2000, Pharmacotherapy.
[22] R. Page,et al. Azimilide dihydrochloride: a new class III anti-arrhythmic agent , 2000, Expert opinion on investigational drugs.
[23] A. Camm,et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.
[24] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[25] S. Doggrell,et al. D-Sotalol: death by the SWORD or deserving of further consideration for clinical use? , 2000, Expert opinion on investigational drugs.
[26] L. Horowitz,et al. Proarrhythmic responses during electrophysiologic testing. , 1987, The American journal of cardiology.
[27] R. Hauer,et al. Genetic and molecular basis of cardiac arrhythmias : Impact on clinical management , 1999 .
[28] J. Mason. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. , 1993, The New England journal of medicine.
[29] S. Hohnloser,et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. , 1999, The New England journal of medicine.
[30] S. S. Hull,et al. K+ Channel Blockade in the Prevention of Ventricular Fibrillation in Dogs with Acute Ischemia and Enhanced Sympathetic Activity , 1995, Journal of cardiovascular pharmacology.
[31] D. Roden. Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. , 1996, Circulation.
[32] A. Camm,et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. , 2000, Cardiovascular research.
[33] E. Vitolo,et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. , 1981, Acta cardiologica.
[34] P. Sager,et al. Frequency-dependent electrophysiologic effects of amiodarone in humans. , 1993, Circulation.
[35] Dimarco Jp,et al. Cardiovascular drugs. Dofetilide. , 2000 .
[36] S. Lévy,et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.
[37] F. Charpentier,et al. Electrophysiologic characteristics of cells spanning the left ventricular wall of human heart: evidence for presence of M cells. , 1995, Journal of the American College of Cardiology.
[38] J Toyama,et al. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. , 1999, The American journal of cardiology.
[40] S. Juul-Möller,et al. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. , 1990 .
[41] L. Virág,et al. Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol , 1997, Journal of cardiovascular pharmacology and therapeutics.
[42] P. Dorian,et al. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. , 1997, Journal of the American College of Cardiology.
[43] E. Carmeliet. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. , 1985, The Journal of pharmacology and experimental therapeutics.
[44] A. Camm,et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.
[45] B. Singh,et al. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. , 1990, Journal of the American College of Cardiology.
[46] M. Pfisterer,et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) , 1990, Journal of the American College of Cardiology.
[47] C Antzelevitch,et al. Acceleration‐Induced Action Potential Prolongation and Early Afterdepolarizations , 1998, Journal of cardiovascular electrophysiology.
[48] J. Kalus,et al. Dofetilide: A Class III-Specific Antiarrhythmic Agent , 2000, The Annals of pharmacotherapy.
[49] E. Aliot,et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.
[50] L. Køber,et al. Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation , 2000, Expert opinion on investigational drugs.
[51] M. Malik,et al. Measurement, interpretation and clinical potential of QT dispersion. , 2000, Journal of the American College of Cardiology.
[52] Kenneth Egstrup,et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.
[53] R. Falk,et al. Dofetilide: a new pure class III antiarrhythmic agent. , 2000, American heart journal.
[54] M. Sanguinetti. Modulation of potassium channels by antiarrhythmic and antihypertensive drugs. , 1992, Hypertension.
[55] Bramahn . Singh,et al. What niche will newer class III antiarrhythmic drugs occupy? , 2001, Current cardiology reports.
[56] A. Camm,et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. , 1999, Circulation.
[57] R. Brooks,et al. Pharmacology of Azimilide Dihydrochloride (NE-10064), A Class III Antiarrhythmic Agent , 1997 .
[58] R. Hart,et al. Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention , 1999, Annals of Internal Medicine.
[59] J. K. Gibson,et al. Electrophysiology and pharmacology of ibutilide. , 1996, The American journal of cardiology.
[60] B. Surawicz. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? , 1989, Journal of the American College of Cardiology.
[61] M. Janse,et al. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.
[62] M. Keating,et al. MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia , 1999, Cell.
[63] L. Carlsson,et al. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. , 1993, Cardiovascular research.
[64] M Gent,et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.
[65] Robert Lemery,et al. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.
[66] H. Elming,et al. The prognostic value of QTC interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide , 2003, Clinical cardiology.
[67] P. Dorian. Mechanisms of action of class III agents and their clinical relevance. , 2000, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[68] M Restivo,et al. The electrophysiological mechanism of ventricular arrhythmias in the long QT syndrome. Tridimensional mapping of activation and recovery patterns. , 1996, Circulation research.
[69] A. Capucci,et al. Clinical Potential of Emerging Antiarrhythmic Agents , 1999, Drugs in R&D.
[70] E. Antman,et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. , 1990, Circulation.
[71] S. Hohnloser,et al. Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications , 1995, Journal of cardiovascular electrophysiology.
[72] E. Antman,et al. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. , 1992, American heart journal.
[73] B. Fermini,et al. Use‐Dependent Effects of the Class III Antiarrhythmic Agent NE‐10064 (Azimilide) on Cardiac Repolarization: Block of Delayed Rectifier Potassium and L‐Type Calcium Currents , 1995, Journal of cardiovascular pharmacology.
[74] D. Roden,et al. Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.
[75] S. Hohnloser,et al. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.
[76] V. Velebit,et al. Aggravation and Provocation of Ventricular Arrhythmias by Antiarrhythmic Drugs , 1982, Circulation.
[77] R. Prescott,et al. CONTROLLED TRIAL OF SOTALOL FOR ONE YEAR AFTER MYOCARDIAL INFARCTION , 1982, The Lancet.
[78] S. Hohnloser,et al. Drug therapy : Sotalol , 1994 .
[79] S Nattel,et al. Effects of the chromanol 293B, a selective blocker of the slow, component of the delayed rectifier K+ current, on repolarization in human and guinea pig ventricular myocytes. , 1998, Cardiovascular research.
[80] D. Wolfe,et al. Ibutilide: a class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter. , 2001, The Journal of emergency medicine.
[81] M. Sanguinetti,et al. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.
[82] M. Morad,et al. Tedisamil blocks the transient and delayed rectifier K+ currents in mammalian cardiac and glial cells. , 1990, The Journal of pharmacology and experimental therapeutics.
[83] D. Roden. Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes , 1998, Pacing and clinical electrophysiology : PACE.
[84] F. Epstein,et al. Electrocardiographic Findings Among the Adult Population of a Total Natural Community, Tecumseh, Michigan , 1965, Circulation.
[85] B F Hoffman,et al. Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length , 1985, Circulation research.
[86] H. Doval,et al. Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.
[87] A. Schömig,et al. Differential Effect of β‐Adrenergic Stimulation on the Frequency‐Dependent Electrophysiologic Actions of the New Class III Antiarrhythmics Dofetilide, Ambasilide, and Chromanol 293. , 1997 .
[88] S. Nattel,et al. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. , 1998, Cardiovascular research.
[89] Bramahn . Singh,et al. Current Antiarrhythmic Drugs , 1999, Journal of cardiovascular electrophysiology.
[90] S. Priori,et al. Low penetrance in the long-QT syndrome: clinical impact. , 1999, Circulation.
[91] Bramahn . Singh,et al. Expanding Indications for the Use of Class III Agents in Patients at High Risk for Sudden Death , 1995, Journal of cardiovascular electrophysiology.
[92] P. Polster,et al. The adrenergic antagonism of amiodarone. , 1976, Biochemical pharmacology.
[93] V. Fuster,et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation , 2001 .
[94] Amiodarone to Prevent Recurrence of Atrial Fibrillation , 2000 .
[95] C. Furberg,et al. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. , 1993, JAMA.
[96] D. Snyders,et al. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.
[97] C Antzelevitch,et al. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. , 1996, Journal of the American College of Cardiology.
[98] A. Hall,et al. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure. , 1999, European heart journal.
[99] S. Connolly,et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.
[100] C Antzelevitch,et al. Chronic Amiodarone Reduces Transmural Dispersion of Repolarization in the Canine Heart , 1997, Journal of cardiovascular electrophysiology.
[101] Bramahn . Singh,et al. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. , 1996, The American journal of cardiology.
[102] M J Ackerman,et al. The long QT syndrome: ion channel diseases of the heart. , 1998, Mayo Clinic proceedings.
[103] Alfred P. Hallstrom,et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. , 1999 .
[104] P. Dorian,et al. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. , 2002, The New England journal of medicine.
[105] J. Williams,et al. Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group. , 1999, The American journal of cardiology.
[106] T. Colatsky,et al. Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. , 1990, Circulation.
[107] E. Antman,et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. , 1993, The American journal of cardiology.
[108] M. Sami,et al. Dofetilide: a new class III antiarrhythmic agent. , 2001, The Canadian journal of cardiology.
[109] M. Sanguinetti,et al. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. , 1993, Circulation research.
[110] P C Deedwania,et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.
[111] P C Deedwania,et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. , 1998, Circulation.
[112] F. Lombardi,et al. Daily reproducibility of electrophysiologic test results in malignant ventricular arrhythmia. , 1986, The American journal of cardiology.
[113] J. Brachmann,et al. Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.
[114] L. Horowitz,et al. Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. , 1988, Journal of the American College of Cardiology.
[115] S. Yusuf,et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. , 1992, Journal of the American College of Cardiology.
[116] Bramahn . Singh,et al. Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide , 2000, Journal of cardiovascular pharmacology and therapeutics.
[117] S. Priori,et al. Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. , 1995, Journal of the American College of Cardiology.
[118] M. Malik,et al. QT Dispersion Has No Prognostic Information for Patients With Advanced Congestive Heart Failure and Reduced Left Ventricular Systolic Function , 2001, Circulation.
[119] L. Køber,et al. Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy , 2001, Circulation.
[120] K. Kuck,et al. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.
[121] G. Butrous,et al. Dofetilide, A Novel Class III Antiarrhythmic Agent , 1992, Journal of cardiovascular pharmacology.
[122] A. Camm,et al. What Should We Expect From the Next Generation of Antiarrhythmic Drugs? , 1999, Journal of cardiovascular electrophysiology.
[123] U. Gerlach,et al. Rate- and site-dependent effects of propafenone, dofetilide, and the new I(Ks)-blocking agent chromanol 293b on individual muscle layers of the intact canine heart. , 1999, Circulation.
[124] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[125] Lippincott Williams Wilkins,et al. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. , 1991, Circulation.
[126] R. Fletcher,et al. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy. , 1999, The American journal of cardiology.